A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
Titel:
A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
Auteur:
Waqar, Saiama N. Redman, Mary W. Arnold, Susanne M. Hirsch, Fred R. Mack, Philip C. Schwartz, Lawrence H. Gandara, David R. Stinchcombe, Thomas E. Leighl, Natasha B. Ramalingam, Suresh S. Tanna, Saloni H. Raddin, Ryan S. Minichiello, Katherine Bradley, Jeffrey D. Kelly, Karen Herbst, Roy S. Papadimitrakopoulou, Vassiliki A.